Cufence ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
58Hypertrophic cardiomyopathy1
171Wilson disease4

58. Hypertrophic cardiomyopathy


Clinical trials : 119 Drugs : 163 - (DrugBank : 45) / Drug target genes : 48 - Drug target pathways : 161
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002242-17-GB
(EUCTR)
30/07/202003/06/2020A trial of trientine in patients with hypertrophic cardiomyopathyA randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy. - TEMPEST Hypertrophic Cardiomyopathy (HCM)
MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Cufence
Product Name: Cufence
INN or Proposed INN: Trientine
Other descriptive name: Triethylinetetramine dihydrochloride
Product Name: Placebo
Manchester University NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
172Phase 2United Kingdom

171. Wilson disease


Clinical trials : 68 Drugs : 79 - (DrugBank : 17) / Drug target genes : 3 - Drug target pathways : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-004604-33-PL
(EUCTR)
16/11/202104/06/2021Multicentre, open-label study to investigate the effects Cufence has, the effects the body has on Cufence and the continued safety and efficacy on patients with Wilson DiseaseOpen label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disease Patients - TR-004 UNITED Study Wilson Disease
MedDRA version: 22.1;Level: PT;Classification code 10019819;Term: Hepato-lenticular degeneration;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Cufence (trientine dihydrochloride)
Product Name: Cufence (trientine dihydrochloride)
INN or Proposed INN: Triethylenetetramine dihydrochloride
Other descriptive name: Cufence
Univar Solutions, B.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 4Poland;Denmark;Germany
2EUCTR2020-004604-33-DK
(EUCTR)
08/10/202111/03/2021Multicentre, open-label study to investigate the effects Cufence has, the effects the body has on Cufence and the continued safety and efficacy on patients with Wilson DiseaseOpen label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disease Patients - TR-004 UNITED Study Wilson Disease
MedDRA version: 22.1;Level: PT;Classification code 10019819;Term: Hepato-lenticular degeneration;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Cufence (trientine dihydrochloride)
Product Name: Cufence (trientine dihydrochloride)
INN or Proposed INN: Triethylenetetramine dihydrochloride
Other descriptive name: Cufence
Univar Solutions, B.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 4Poland;Denmark;Germany
3EUCTR2020-004604-33-DE
(EUCTR)
23/02/202117/12/2020Multicentre, open-label study to investigate the effects Cufence has, the effects the body has on Cufence and the continued safety and efficacy on patients with Wilson DiseaseOpen label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disease Patients - TR-004 UNITED Study Wilson Disease
MedDRA version: 22.1;Level: PT;Classification code 10019819;Term: Hepato-lenticular degeneration;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Cufence (trientine dihydrochloride)
Product Name: Cufence (trientine dihydrochloride)
INN or Proposed INN: Triethylenetetramine dihydrochloride
Other descriptive name: Cufence
Univar Solutions, B.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 4France;Poland;Denmark;Germany
4EUCTR2020-004604-33-FR
(EUCTR)
12/03/2021Multicentre, open-label study to investigate the effects Cufence has, the effects the body has on Cufence and the continued safety and efficacy on patients with Wilson DiseaseOpen label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disease Patients - TR-004 UNITED Study Wilson Disease
MedDRA version: 22.1;Level: PT;Classification code 10019819;Term: Hepato-lenticular degeneration;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Cufence (trientine dihydrochloride)
Product Name: Cufence (trientine dihydrochloride)
INN or Proposed INN: Triethylenetetramine dihydrochloride
Other descriptive name: Cufence
Univar Solutions, B.V.NULLNAFemale: yes
Male: yes
50Phase 4France;Poland;Denmark;Germany